In-line prediction of drug release profiles for pH-sensitive coated pellets

The Analyst ◽  
2011 ◽  
Vol 136 (22) ◽  
pp. 4830 ◽  
Author(s):  
Alexey L. Pomerantsev ◽  
Oxana Ye. Rodionova ◽  
Michael Melichar ◽  
Anthony J. Wigmore ◽  
Andrey Bogomolov
2014 ◽  
Vol 2 (37) ◽  
pp. 6271-6282 ◽  
Author(s):  
Zhongyu Duan ◽  
Yu-Juan Gao ◽  
Zeng-Ying Qiao ◽  
Gang Fan ◽  
Ya Liu ◽  
...  

In this work, we prepared PEG modified poly(β-amino ester) graft copolymers with pH-sensitive properties. Doxorubicin (DOX) and squaraine (SQ) dye as a photoacoustic tomography (PAT) reporter molecule were loaded into the hydrophobic core of polymeric micelles, and their release profiles investigated using the PAT technique.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 260
Author(s):  
Mariana Morais ◽  
Patrícia Coimbra ◽  
Maria Eugénia Pina

The visual impairment that often leads to blindness causes a higher morbidity rate. The goal of this work is to create a novel biodegradable polymeric implant obtained from coaxial fibers containing the dispersed drug—acetazolamide—in order to achieve sustained drug release and increase patient compliance, which is of the highest importance. Firstly, during this work, uncoated implants were produced by electrospinning, and rolled in the shape of small cylinders that were composed of uniaxial and coaxial fibers with immobilized drug inside. The fibers were composed by PCL (poly ε-caprolactone) and Lutrol F127 (poly (oxyethylene-b-oxypropylene-b-oxyethylene)). The prepared implants exhibited a fast rate of drug release, which led to the preparation of new implants incorporating the same formulation but with an additional coating film prepared by solvent casting and comprising PCL and Lutrol F127 or PCL and Luwax EVA 3 ((poly (ethylene-co-vinyl acetate)). Implants were characterized and in vitro release profiles of acetazolamide were obtained in phosphate buffered saline (PBS) at 37 °C. The release profile of the acetazolamide from coated implant containing Luwax EVA 3 is considerably slower than what was observed in case of coated implants containing Lutrol F127, allowing a sustained release and an innovation relatively to other ocular drug delivery systems.


2017 ◽  
Vol 78 ◽  
pp. 674-681 ◽  
Author(s):  
Natalia I. Cuello ◽  
Verónica R. Elías ◽  
Silvia N. Mendieta ◽  
Marcela Longhi ◽  
Mónica E. Crivello ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document